- Home
- PAYC vs ROIV Comparison
PAYC vs ROIV Comparison
Compare PAYC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYC
- ROIV
- Stock Information
- Founded
- PAYC 1998
- ROIV 2014
- Country
- PAYC United States
- ROIV United Kingdom
- Employees
- PAYC N/A
- ROIV N/A
- Industry
- PAYC Computer Software: Prepackaged Software
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- PAYC Technology
- ROIV Health Care
- Exchange
- PAYC Nasdaq
- ROIV Nasdaq
- Market Cap
- PAYC 13.3B
- ROIV 8.4B
- IPO Year
- PAYC 2014
- ROIV N/A
- Fundamental
- Price
- PAYC $203.35
- ROIV $10.94
- Analyst Decision
- PAYC Hold
- ROIV Strong Buy
- Analyst Count
- PAYC 10
- ROIV 8
- Target Price
- PAYC $204.50
- ROIV $17.93
- AVG Volume (30 Days)
- PAYC 565.1K
- ROIV 5.3M
- Earning Date
- PAYC 02-05-2025
- ROIV 02-11-2025
- Dividend Yield
- PAYC 0.74%
- ROIV N/A
- EPS Growth
- PAYC 42.02
- ROIV N/A
- EPS
- PAYC 8.29
- ROIV 5.89
- Revenue
- PAYC $1,823,922,000.00
- ROIV $129,128,999.00
- Revenue This Year
- PAYC $12.65
- ROIV $15.98
- Revenue Next Year
- PAYC $10.32
- ROIV N/A
- P/E Ratio
- PAYC $24.51
- ROIV $1.86
- Revenue Growth
- PAYC 11.92
- ROIV 145.68
- 52 Week Low
- PAYC $139.50
- ROIV $9.69
- 52 Week High
- PAYC $242.74
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- PAYC 40.64
- ROIV 38.75
- Support Level
- PAYC $197.12
- ROIV $10.42
- Resistance Level
- PAYC $203.79
- ROIV $11.82
- Average True Range (ATR)
- PAYC 4.95
- ROIV 0.35
- MACD
- PAYC -0.73
- ROIV -0.11
- Stochastic Oscillator
- PAYC 34.36
- ROIV 29.21
About PAYC Paycom Software Inc.
Paycom is a fast-growing provider of payroll and human capital management software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 19,500 clients as of 2023, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.